General description
Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.
INN
Cytarabine
ATC codes
Medicine type
Chemical agent
EML status history
First added in 1979
(TRS
641)
for
Lymphoid leukaemia, not elsewhere classified
Added in 1979
(TRS
641)
for
Myeloid leukaemia
Added in 1979
(TRS
641)
for
Acute myeloid leukaemia with recurrent genetic abnormalities
Added in 1979
(TRS
641)
for
Burkitt lymphoma including Burkitt leukaemia
Added in 1979
(TRS
641)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-positive
Added in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-negative
Added in 2023
(TRS
1049)
for
Langerhans cell histiocytosis
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Indications
Lymphoid leukaemia, not elsewhere classified
Myeloid leukaemia
Acute myeloid leukaemia with recurrent genetic abnormalities
Burkitt lymphoma including Burkitt leukaemia
Unspecified malignant neoplasms of ill-defined or unspecified sites
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative
Langerhans cell histiocytosis